Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ION224 in NASH
NCT04932512Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- Jan 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of IONIS-DGAT2Rx in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Ionis Pharmaceuticals. Primary endpoint: Percentage of Participants With at Least 2-point Reduction in Non-alcoholic Fatty Liver Disease Activity Score (NAS) With at least 1-point Improvement in Hepatocellular Ballooning or Lobular… at 49 weeks. Started Jun 2021; status: completed.
02
Drugs
IONIS-DGAT2Rx
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04932512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04932512.